Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages.
Song M, Yeku OO, Rafiq S, Purdon T, Dong X, Zhu L, Zhang T, Wang H, Yu Z, Mai J, Shen H, Nixon B, Li M, Brentjens RJ, Ma X.
Nat Commun. 2020 Dec 8;11(1):6298. doi: 10.1038/s41467-020-20140-0.
Endometriosis-Associated Ovarian Cancer: From Molecular Pathologies to Clinical Relevance.
Steinbuch SC, Lüß AM, Eltrop S, Götte M, Kiesel L.
Int J Mol Sci. 2024 Apr 13;25(8):4306. doi: 10.3390/ijms25084306.
Pathogenesis of Endometriosis and Endometriosis-Associated Cancers.
Adilbayeva A, Kunz J.
Int J Mol Sci. 2024 Jul 11;25(14):7624. doi: 10.3390/ijms25147624.
A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC, Oikkonen J, Bulanova D, Pietras EJ, Voßgröne K, Chen YJ, Erkan EP, Dai J, Lundgren A, Grønning Høg MK, Larsen IM, Lamminen T, Kaipio K, Huvila J, Virtanen A, Engelholm L, Christiansen P, Santoni-Rugiu E, Huhtinen K, Carpén O, Hynninen J, Hautaniemi S, Vähärautio A, Wennerberg K.
Dev Cell. 2023 Jun 19;58(12):1106-1121.e7. doi: 10.1016/j.devcel.2023.04.012. Epub 2023 May 5.
Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy.
Meng Y, Qiu L, Zeng X, Hu X, Zhang Y, Wan X, Mao X, Wu J, Xu Y, Xiong Q, Chen Z, Zhang B, Han J.
Signal Transduct Target Ther. 2022 Dec 9;7(1):388. doi: 10.1038/s41392-022-01253-y.
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations.
Schouten PC, Schmidt S, Becker K, Thiele H, Nürnberg P, Richters L, Ernst C, Treilleux I, Medioni J, Heitz F, Pisano C, Garcia Y, Petru E, Hietanen S, Colombo N, Vergote I, Nagao S, Linn SC, Pujade-Lauraine E, Ray-Coquard I, Harter P, Hahnen E, Schmutzler RK.
JAMA Netw Open. 2024 Apr 1;7(4):e245552. doi: 10.1001/jamanetworkopen.2024.5552.
The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer.
Nowak M, Klink M.
Cells. 2020 May 22;9(5):1299. doi: 10.3390/cells9051299.
The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH, Seow KM, Chen KH.
Int J Mol Sci. 2022 Jul 23;23(15):8125. doi: 10.3390/ijms23158125.
Perspectives on pure ovarian stromal neoplasms and tumor-like proliferations of the ovarian stroma.
Roth LM, Czernobilsky B.
Am J Surg Pathol. 2011 Mar;35(3):e15-33. doi: 10.1097/PAS.0b013e31820acb89.
N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma.
Miranda A, Pattnaik S, Hamilton PT, Fuss MA, Kalaria S, Laumont CM, Smazynski J, Mesa M, Banville A, Jiang X, Jenkins R, Cañadas I, Nelson BH.
Sci Adv. 2024 May 17;10(20):eadj5428. doi: 10.1126/sciadv.adj5428. Epub 2024 May 15.
